OPU
XLRN

Omni Partners US’s Acceleron Pharma XLRN Stock Holding History

Omni Partners US’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$5.08M Buy
+29,500
New +$3.86M 0.26% 74

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Omni Partners US's XLRN Position: Q3 2021 in Review

Omni Partners US opened a new position in Acceleron Pharma (XLRN) in Q3 2021: 29,500 shares worth $5.08M. The stake represents 0.26% of the portfolio and ranks #74 among its holdings.

330 funds tracked by Wall St. Rank hold XLRN as of Q3 2021.

  • Omni Partners US held 29,500 shares of Acceleron Pharma worth $5.08M as of Q3 2021.
  • Acceleron Pharma was a new Omni Partners US position in Q3 2021.
  • Acceleron Pharma made up 0.26% of Omni Partners US's portfolio in Q3 2021, its #74 holding.
  • 330 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2021.

Based on Omni Partners US's 13F filing for Q3 2021, filed 15 Nov 2021.